Tirzepatide vs Semaglutide: What to Know

Everyone seems to have an opinion on which treatment works better, but very few explain the actual biology behind why they're different. Tirzepatide, sold in Canada as Mounjaro, works on two hormone receptor pathways, while semaglutide, available as Ozempic, Rybelsus, and Wegovy, works on one, and that's just the starting point for how Health Canada has reviewed each, what clinical trial data shows for weight and blood sugar, and what a provider weighs on safety before prescribing either. We're breaking down the mechanisms, approvals, research, and practical factors side by side, so you have the full picture before your next conversation with a provider.

TLDR:

• Tirzepatide acts on two hormone receptors (GIP and GLP-1); semaglutide targets GLP-1 alone.
• Health Canada reviews both through a formal process, publishing safety and quality findings for each.
• Nausea, diarrhea, constipation, and vomiting are common with both, especially during dose changes.
• A licensed provider weighs medical history, current prescriptions, and personal preference before considering either option.
• Phoenix is a Canadian men's digital health clinic connecting patients with licensed healthcare providers for online medical assessments.

What Is Tirzepatide?

Tirzepatide is a prescription treatment classified as a dual GIP and GLP-1 receptor agonist, acting on two hormone receptors involved in blood sugar and digestion: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).

How Tirzepatide Is Administered

It is given as an injection under the skin. In Canada, tirzepatide is available through products approved by Health Canada for specific medical uses, and a licensed healthcare provider determines whether it fits a patient's health profile.

Working on two receptor types instead of one is simply a description of its mechanism, not a claim about results. Providers weigh medical history, current health, and treatment goals before considering this option.

What Is Semaglutide?

Semaglutide is a prescription treatment classified as a GLP-1 receptor agonist, acting on a single hormone receptor called glucagon-like peptide-1, which plays a role in blood sugar regulation and digestion.

Available Formats and Health Canada Authorization

In Canada, semaglutide is available in more than one prescription format, including an injection given under the skin and an oral tablet. Health Canada has authorized specific semaglutide products for defined medical uses, and a licensed healthcare provider reviews a patient's health history before determining whether either format is appropriate for that individual.

Working on one receptor type is a functional description, not an outcome claim. Suitability always depends on factors a provider assesses directly.

How Do Their Mechanisms of Action Compare?

Semaglutide activates a single pathway, the GLP-1 receptor, which plays a general role in digestion, appetite signaling, and blood sugar regulation in the body.

Single vs. Dual Receptor Pathways

Tirzepatide activates two pathways, both GIP and GLP-1 receptors. GIP is a hormone that plays a general role in insulin regulation and fat metabolism, working alongside GLP-1 instead of replacing it. A StatPearls clinical reference on dual receptor action describes this combined activity as central to how the treatment functions.

Which Pathway Fits a Patient

Neither pathway is inherently better on paper. Single versus dual receptor activity are different biological routes toward managing appetite signals and blood sugar, and the right fit depends on individual health history as determined by a licensed provider.

How Does Regulatory Approval Compare in Canada?

How Health Canada Reviewed Each Brand

Health Canada has reviewed both treatments through its formal process, publishing a Summary Basis of Decision for each that covers safety, effectiveness, and quality findings. The decision summary for Mounjaro outlines this review. The summary is updated as new submissions or indications come through.

Generic Semaglutide Authorization

On the generic side, Health Canada authorized a generic semaglutide injection for weight loss in June 2026, with six more submissions under review at the time. This affects supply and access, not how the original brand products were reviewed. For a closer look at how generic semaglutide compares to Ozempic and Wegovy in Canada, bioequivalence and pricing are key factors to consider.

Neither authorization means regulators favor one treatment over the other. Both remain prescription-only and subject to change, so treat any approval detail here as a snapshot, not a permanent fact.

What Does Clinical Research Say About Weight Loss and Diabetes Outcomes?

Large randomized trials have tracked weight-related outcomes for both treatment categories over extended periods. The SURMOUNT-1 trial (2022, 72 weeks) reported reductions of up to 22.5%, and the STEP 1 trial (2021, 68 weeks) reported reductions of up to 14.9%. Both trials also tracked secondary measures, including waist circumference and markers linked to blood sugar regulation, alongside discontinuation rates tied to side effects. These figures describe outcomes within controlled trial populations, not a guarantee for any individual, and a licensed provider weighs a patient's health history, goals, and other approved medical uses before considering either option. Actual results vary widely from person to person, which is why ongoing monitoring by a provider matters more than any published average.

A separate head-to-head trial, SURMOUNT-5, compared the two treatments directly in adults with obesity or overweight. Participants using tirzepatide lost an average of 22.9 kg (about 50.3 lbs) over the study period, compared to an average of 15 kg (about 33.1 lbs) among participants using semaglutide. As with the other trial figures in this section, these are controlled study averages, not a prediction for any one person. A higher-dose semaglutide formulation, sold as Wegovy at 7.2 mg and studied in the STEP UP trial, produced average weight reductions of around 21%, narrowing the gap seen in some comparisons, though gastrointestinal side effects were reported more often at this higher dose. Individual results still depend on factors like adherence, dose, and how a person's body responds over time.

A more recent head-to-head tirzepatide and semaglutide trial compared the two treatment categories directly instead of relying on separate studies. Published in The New England Journal of Medicine in 2025, it followed adults with obesity for 72 weeks and reported an average weight reduction of 20.2% among participants using the highest studied tirzepatide doses, compared to 13.7% among participants using the highest studied semaglutide dose. A separate higher-dose semaglutide clinical trial, published in 2025, reported average weight reductions of up to 18.7%, narrowing some of the gap seen in the head-to-head comparison, though gastrointestinal side effects were reported more often at the higher dose studied. As with the other figures in this section, these are trial averages, not a prediction for any one person.

Diabetes-focused trials have also compared the two categories directly. The SURPASS-2 diabetes trial, published in The New England Journal of Medicine in 2021, followed people with type 2 diabetes for 40 weeks and reported average A1C (a measure of blood sugar control) reductions of up to 2.3 percentage points among those on the highest studied tirzepatide dose, compared to 1.86 percentage points among those on the studied semaglutide dose. These are trial averages within a specific patient population, and a licensed provider factors your own diabetes history and current prescriptions into any recommendation.

How Do Administration and Format Considerations Compare?

Format is one of the more practical differences between these two treatment categories. Tirzepatide is currently available only as an injection given under the skin, while semaglutide is available in more than one format, including an injection and an oral tablet, giving patients considering semaglutide an additional option to discuss. Neither format is inherently easier to manage than the other: comfort with self-injection and tolerance for a daily pill both vary from person to person. Storage, handling, and administration instructions differ by product and come directly from the dispensing pharmacy, so patients should follow the guidance included with their specific prescription instead of general assumptions found online. A licensed healthcare provider factors format preference in alongside medical history and other health details when discussing which option may fit a patient's routine.

How Do Side Effects and Safety Profiles Compare?

Common Digestive Side Effects

Both treatment categories share a similar side effect pattern, since each works through related digestive and appetite pathways. Nausea, diarrhea, constipation, and vomiting are the most commonly reported effects, particularly when a dose is increased: a pattern covered in detail in a week-by-week GLP-1 side effects guide. These effects often ease as the body adjusts, though this varies from person to person.

Boxed Warning and Contraindications

Beyond digestive symptoms, both treatment categories carry a Serious Warnings and Precautions notice in their Health Canada product monographs, related to a risk of thyroid C-cell tumors, including medullary thyroid carcinoma. Both are contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and a licensed provider reviews this and other contraindications against your full medical history before considering either option. Readers comparing options may also find it useful to review personal and family medical history, current prescriptions, and any conditions that might affect suitability. No treatment in this category is free of risk.

Talking to a Provider About Tolerability

Because tolerability differs from person to person, a direct conversation with a provider is more useful than a generic list. A licensed healthcare provider can review your history, flag contraindications, and monitor your response if treatment begins.

What Factors Might Influence Which Option a Provider Considers?

A provider weighs more than a single data point when considering these options. Personal and family medical history comes first, since certain conditions or past reactions can rule one path out, and factors like preserving muscle during GLP-1 weight loss are also worth discussing with a provider.

Factors a Provider Typically Reviews

Other factors typically reviewed include:

• Tolerance to digestive side effects, since some people adjust more easily than others as a dose changes
• Other approved medical uses that may already apply to a patient's health profile
• Current prescriptions and how they might interact with a new treatment
• Personal preference around format and injection frequency
• Response to any prior treatment in this category, if applicable

How These Factors Come Together

A licensed healthcare provider reviews these together, alongside lab work where relevant, since what fits one patient may not fit another. This includes considerations around what makes GLP-1 different for men.

How Can Canadians Access These Treatments Online?

Getting access to either treatment online usually starts with a health questionnaire instead of an in-person visit, and patients can review generic semaglutide in Canada for background on what to expect. You answer questions about medical history, current prescriptions, and health goals, and a licensed healthcare provider reviews that information to determine whether a prescription treatment is appropriate for your situation. No treatment is guaranteed just because you complete an assessment.

Phoenix is a Canadian men's digital health clinic that connects patients with licensed healthcare providers for online medical assessments.

Coverage through provincial or private plans varies widely and changes over time, so confirm any coverage detail directly with your plan provider as of late 2026. Out-of-pocket costs are explained in more detail on the Ozempic and generic semaglutide pricing page. What one employer benefits plan or provincial formulary covers today may look different in a few months, and eligibility rules differ by province and by plan.

Frequently Asked Questions About Tirzepatide and Semaglutide

Is tirzepatide or semaglutide more effective for weight loss?

Neither treatment category is classified as more effective than the other: outcomes vary by individual, and a licensed healthcare provider reviews your health profile before considering either option. The trial data covered above offers a general picture, but your own results depend on factors like adherence, dose, and how your body responds over time.

Can I switch between tirzepatide and semaglutide?

Switching from one treatment category to another is a decision your provider makes after reviewing your history with the current treatment, including how you tolerated it and whether it met your goals. Any change in treatment should go through a licensed healthcare provider instead of being adjusted on your own.

Do tirzepatide and semaglutide cause the same side effects?

Both treatment categories share a similar side effect profile, since each works through related digestive and appetite pathways. Nausea, diarrhea, constipation, and vomiting are the most commonly reported effects, especially during dose changes, though how strongly you notice them varies from person to person.

What are the brand names for tirzepatide and semaglutide in Canada?

Tirzepatide is sold in Canada under the brand name Mounjaro, from Eli Lilly. Semaglutide is available under several brand names, including Ozempic, Rybelsus, and Wegovy, from Novo Nordisk, along with an authorized generic semaglutide injection. Each brand covers specific approved uses, and a licensed healthcare provider confirms which product applies to your situation.

Which option shows better results for type 2 diabetes in clinical trials?

A head-to-head trial called SURPASS-2, published in The New England Journal of Medicine in 2021, followed people with type 2 diabetes for 40 weeks and reported average A1C reductions of up to 2.3 percentage points among those on the highest studied tirzepatide dose, compared to 1.86 percentage points among those on the studied semaglutide dose. These are trial averages, not individual guarantees, and a licensed provider weighs your diabetes history and current medications before recommending either option.

How does a provider decide which option might fit me?

A provider looks at your personal and family medical history, current prescriptions, and any prior response to treatment in this category before considering either option. Format preference and your tolerance for digestive side effects factor in too, since what suits one patient may not suit another.

Does Health Canada consider one option safer than the other?

Health Canada reviews both treatment categories through the same formal process and publishes a Summary Basis of Decision for each, covering safety, effectiveness, and quality findings. Neither authorization signals that one category is favoured over the other, and both remain prescription-only and subject to ongoing review.

Final Thoughts on Sorting Through Tirzepatide and Semaglutide

Comparing these two treatments comes down to more than mechanism alone. Your provider looks at your medical history, current prescriptions, and how your body tends to respond before suggesting any direction. That kind of individual review is what turns a general overview like this one into something useful for your own health. From here, the next move is simply a conversation with a licensed provider who can apply these details to your situation.